bluuebunny/crossref_metadata_2025_split huggingface dataset:
Transcatheter Closure of Patent Ductus Arteriosus With Severe Pulmonary Artery Hypertension Through Single Venous Approach: a Propensity Score Match Analysis From Long-term Outcomes
Authors: Hu Danqing , Chen En , Cai Wei , Chen Lianglong 
Published: May 2021

Abstract
Background: Up to now, transcatheter closure of patent ductus arteriosus(PDA) without severe pulmonary artery hypertension (PAH) has been well established and accepted in clinical practice. However, in PDA patients with severe PAH, transcatheter closure still remains a challenge, regardless of the tremendous advancement in devices and techniques.Methods: We reviewed the records of PDA patients who underwent transcatheter device closure though single femoral venous approach between January 2005 and December 2018. Severe PAH was defined as systolic pulmonary artery pressure (SPAP) measured by a catheter >70mmHg, excluding irreversible severe PAH assessed by trial occlusion. Propensity score matching was used to assemble a cohort of patients with similar baseline characteristics. Results: A total of 29 patients were in severe PAH (SPAH) group after excluding 2 for failing to the trial occlusion, and 468 in non-severe PAH(non-SPAH) group. After matching, 25 patients were in SPAH group, and 39 in non-SPAH group, without any significant difference in baseline characteristics. The median follow-up periods were 57 and 44 months for groups, respectively. No signiﬁcant difference was noted in the rates of cumulative adverse events in the 2 groups (p=0.208). No poor effects in left ventricular function and residual shunt evaluated by transthoracic echocardiography(TTE) in SPAH group were detected in the short- and long-term follow-up.Conclusion: In the patients with PDA associated with reversible severe PAH, compared to non-severe PAH, transcatheter closure through single venous approach has comparable adverse events rates and successful closure rate, with equivalent results of TTE examination at the short- and long-term follow-up.
The Vertical Distribution Pattern of Microbial- and Plant-Derived Carbon in the Rhizosphere in Alpine Coniferous Forests
Authors: Gao Wentong , Wang Qitong , Zhu Xiaoming , Liu Zhanfeng , Li Na , Xiao Juan , Sun Xiaoping , Huajun Yin 
Published: May 2021

Abstract
Background and aimsWhile the quantitative assessment of plant- and microbial-derived carbon (C) in the soil organic C (SOC) chemical composition in soil profiles has been initially explored, the vertical distribution pattern of these two C sources and their dominant role in SOC formation based on the insights related to the rhizosphere are still lacking.MethodsWe quantified the divergent accumulation of microbial-derived C (i.e., microbial residues), plant-derived C (i.e., lipids and lignin phenols) and SOC in the rhizosphere at various depths (0-10 cm, 10-20 cm and 20-30 cm) in the upper mineral soil and analyzed its control factors in an alpine coniferous forest (Picea asperata. Mast). We further revealed the relative contribution of plant- or microbial-derived C to rhizosphere SOC in the soil profile.ResultsThe contents of microbial- and plant-derived C and SOC in the rhizosphere decreased with soil depth and were mainly regulated by root and microbial biomass. Moreover, the contribution of microbial-derived C dominated by fungal residues to rhizosphere SOC at each soil depth (more than 62%) was much higher than that of plant-derived C (less than 6%), implying that the soil microbial C pump was intensely stimulated in the rhizosphere.ConclusionsThese results indicated that microbial-derived C was the main contributor of rhizosphere SOC at various depths in the upper mineral soil. Our findings provide direct experimental evidence for assessing the dominant contribution of microbial- or plant-derived C to SOC in the soil profile from the perspective of the rhizosphere.
Outcomes of Stereotactic Radiosurgery in Young Adults With Vestibular Schwannomas
Authors: Kawashima Mariko , Hasegawa Hirotaka , Shin Masahiro , Shinya Yuki , Katano Atsuto , Saito Nobuhito 
Published: May 2021

Abstract
Purpose: Vestibular schwannomas (VSs) are comparatively rare in younger patients, and stereotactic radiosurgery (SRS) outcome data are limited. We aimed to evaluate long-term SRS outcomes concerning sporadic VSs in patients aged ≤ 40 years. Methods: Of 383 patients with VS who had undergone SRS at our institution between 1990 and 2017, we compared younger and older patients’ tumor control and radiation-induced complication rates using case‒control propensity score (PS) matching.Results: The mean follow-up was 83 and 92 months in older and younger patients, respectively. Compared with older patients, younger patients were more likely to have a history of resection (20% vs. 39%, p = 0.006) and be treated with higher marginal doses (median, 12 Gy vs. 14 Gy; p = 0.014). Cumulative 5- and 10-year tumor control rates were higher in older patients (97.7% and 93.9%, respectively) than in younger patients (90.2% and 85.4%, respectively, p = 0.024). After PS matching, younger patients’ cumulative tumor control rates (93.6%, 85.4%, and 85.4% at 5, 10, and 15 years, respectively) were similar to those of older patients (p = 0.411). No significant between-cohort differences in hearing preservation rates or facial and trigeminal nerve complications were observed. Two younger patients had malignant tumors several years post-SRS, with one patient having confirmed histological transformation. Conclusions: SRS is equally effective for younger and older patients. Complications other than hearing deterioration are uncommon. Malignant transformation is possible and long-term post-SRS surveillance MRI is important. These data are useful for decision-making involving young adults with VSs.
Degeneracy of Light Scattering and Absorption by a Single Nanowire
Authors: Lee Jeng Yi , Chen Yi-Huan , Chen Pai-Yen 
Published: May 2021

Abstract
We theoretically and numerically prove that under an electromagnetic plane wave with linear polarization incident normally to a single nanowire, there exists a power diagram that could indicate scattering properties for any system configurations. We demonstrate the distinct power distribution boundary in absorption, scattering, and extinction for a generalized nanowire with any partial wave modes dominant. In the boundary, each dominant scattering coefficients remain constant, and its energy performance would display superabsorbers or superscatterers. Interestingly, for a system with larger partial wave modes dominant, the occupied domain in the power diagram could completely cover that with lower ones. Hence, a system with different levels of partial wave modes can display the same power results, reflecting the degeneracy. This degenerate property could release more degrees of freedom in designs of energy harvesting devices and sensors. We demonstrate several systems based on realistic materials to support our findings.
Long noncoding LINC00238 restrains Hepatocellular Carcinoma Malignant Phenotype via Sponging miR-522
Authors: Qian Honggang , Wu Qiong , Wu Jian-Hui , Tian Xiu-Yun , Xu Wei , Hao Chun-Yi 
Published: May 2021

Abstract
Background: Long noncoding RNA (lncRNA) Can regulates tumor malignant phenotype either as a tumor suppressor or an oncogene. In hepatocellular carcinoma (HCC), the clinical significance and underlying mechanism of LINC00238 function remain undefined. Methods: Down-regulated expression levels of noncoding RNAs were screened from TCGA LIHC dataset through GEPIA software. The expression of RNAs were determined by qRT-PCR. Molecular clone was performed to over-expression and knockdown of LINC00238 expression. The levels of proteins were evaluated via Western blot. The cell viability, clone formation and migration ability were assessed by CCK-8, plate clone formation and Transwell assays. RNA pull down and Luciferase reporter assays were applied to detect the interplays between LINC00992 and miR-3935.Results: LINC00238 was identified as a significant downregulated both in TCGA and in our cohort, and its low expression was significantly correlated with bigger tumor size, early recurrence and poor survival of patients with HCC after surgery. Through the results of gain and loss of function experiments, LINC00238 was confirmed as a tumor suppressor， which could decrease not only cell viability, migration and invasion in vitro but also tumorigenesis and tumor metastasis in vivo. Mechanistically, RNA pull-down showed that LINC00238 sponged mir-522, and then, released the inhibition effects on two downstream targets, SFRP2 and DKK1.Conclusions: We identified LINC00238 as a tumor suppressor by sponging miR-522 followed by release silencing of downstream targets, suggesting that LINC00238 has a key role in restraining the malignant phenotype of HCC cells and providing a novel perspective on lncRNAs in HCC progression.
Breast Angiosarcoma: a SEER Population- Based Study
Authors: Xu Zhengshui , Li Xiaopeng , Guo Jing , Yuan Liyue , Chen Zilu , Zheng Jianbao , Sun Xuejun , Yu Junhui 
Published: May 2021

Abstract
Background

Breast angiosarcoma is a rare malignancy with poor survival. Due to the paucity of data, the generation of high-quality evidence for its high-risk features and the impact of treatment modalities on survival have been hampered.
Objective

To examine high-risk features and the impact of treatment modalities on disease-specific survival (DSS) in breast angiosarcoma and differences between breast angiosarcoma cases with and without other prior cancers.
Methods

In this retrospective study, patients with breast angiosarcoma diagnosed from 1975 to 2016 were identified from the Surveillance, Epidemiology, and End Results database. Cox proportional hazards regression analysis adjusted for age, race, decade at diagnosis, location, pathologic grade, extent of disease, tumor size, and therapy to model DSS outcomes. Propensity score matching analyses were performed to adjust for the differences between breast angiosarcoma cases with and without other prior cancers to compare their DSS values. A Kaplan-Meier curve was used to visualize the cumulative survival probability.
Results

Of 648 patients with breast angiosarcoma, 55.4% had a prior cancer diagnosis. Older (age ≥ 70) patients were more likely to have breast angiosarcoma with prior cancer than younger patients (64.3% versus 21.8%). Via multivariate analysis, pathologic grade and extent of disease were identified to be significantly associated with DSS in breast angiosarcoma. In matched data, breast angiosarcoma patients with prior cancer had a better DSS than those without prior cancer (HR = 0.60, 95%CI 0.38–0.96, p = 0.0389). In breast angiosarcoma patients without prior cancer, patients with larger tumor size receiving surgery plus radiation or/and chemotherapy might have a better survival than those patients receiving surgery only (HR = 0.38, 95%CI 0.14–0.99, p = 0.0128). DSS is not impacted by the current therapeutic strategies in unselected breast angiosarcoma patients.
Conclusions

Breast angiosarcoma patients with prior cancer have a better DSS than those without prior cancer. Additionally, some breast angiosarcoma cases with prior cancer may be cutaneous angiosarcomas. Pathologic grade and extent disease are high-risk features. DSS is not impacted by the current therapeutic strategies in unselected breast angiosarcoma patients.
Efficacy and Toxicity of Different Concurrent Chemoradiotherapy Regimens in Patients With Locally Advanced Non-Small Cell Lung Cancer-a Network Meta-Analysis­
Authors: Zheng Qiang-qiang , Min Shi-hui , Zhou Qing-hua 
Published: May 2021

Abstract
Background: Concurrent chemoradiotherapy (CCRT) is the cornerstone treatment for patients with locally advanced non-small cell lung cancer (LA-NSCLC). The aim of this study was to compare the efficacy and toxicity of different CCRT regimens in the treatment of LA-NSCLC by adopting a network meta-analysis.Methods: PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) were exhaustively searched to identify relevant studies from inception up to October 1, 2020. Direct and indirect evidence were combined to calculate the odds radio (OR) and its 95% confidence interval (CI), as well as to draw the surface under the cumulative ranking (SUCRA) curves. Cluster analyses were adopted to compare efficacy and toxicity of different CCRT regimens according to the similarity of 2 variables. Publication bias was detected by comparison-adjusted funnel plot.Results: Twenty-two studies were enrolled in this network meta-analysis, including 18 CCRT regimens: CCRT (cisplatin+etoposide), CCRT (carboplatin+paclitaxel), CCRT (pemetrexed+carboplatin), CCRT (pemetrexed+cisplatin), CCRT (docetaxel+cisplatin), CCRT (S-1+cisplatin), CCRT (mitomycin+vindesine+cisplatin), CCRT (cisplatin+vinorelbine), CCRT (cisplatin), CCRT (etoposide+cisplatin+amifostine), RT, CCRT (5-FU), CCRT (paclitaxel+cisplatin), CCRT (irinotecan+carboplatin), CCRT (nedaplatin), CCRT (carboplatin+etoposide), CCRT (paclitaxel), and CCRT (carboplatin). The results indicated that the regimens with CCRT (cisplatin+etoposide), CCRT (carboplatin+paclitaxel), CCRT (pemetrexed+cisplatin), CCRT (S-1+cisplatin), and CCRT (cisplatin+vinorelbine) had relatively better efficacy compared with other regimens. As for toxicity of different CCRT regimens, the CCRT (carboplatin+paclitaxel), CCRT (pemetrexed+cisplatin), and CCRT (docetaxel+cisplatin) were relatively lower.Conclusions: Our study demonstrated that CCRT (pemetrexed+cisplatin) and CCRT (carboplatin+paclitaxel) might be the best choice of CCRT regimens in the treatment of LA-NSCLC, and the 3-year overall survival (OS) rate of CCRT (pemetrexed+cisplatin) was the highest among these regimens.
Essential Dynamics for Developing Models for Control of Connected and Automated Electrified Vehicles: Part A - Powertrain
Authors: Hemmati Sadra , yadav Rajeshwar , Surresh Kaushik , Robinette Darrell , Shahbakhti Mahdi 
Published: May 2021

Abstract
Connected and Automated Vehicles (CAV) technology presents significant opportunities for energy saving in the transportation sector. CAV technology forecasts vehicle and powertrain power needs under various terrain, ambient, and traffic conditions. Even though the CAV technology is applicable to both conventional and electrified powertrains, the energy saving opportunities are more apparent when the CAVs are Hybrid Electric Vehicles (HEVs). This is because of the flexibility in the vehicle powertrain and possibility of choosing optimum powertrain modes based on the predicted traction power needs. In this paper, the powertrain dynamics essential for developing powertrain controllers for a class of connected HEVs is presented. To this end, control-oriented powertrain dynamic models for a test vehicle consisting of full electric, hybrid, and conventional engine operating modes are developed. The resulting powertrain model can forecast vehicle traction torque and energy consumption for the specified prediction horizon of the test vehicle. The model considers different operating modes and associated energy penalty terms for mode switching. Thus, the vehicle controller can determine the optimum powertrain mode, torque, and speed for forecasted vehicle operation via utilizing connectivity data. The powertrain model is validated against the experimental data and shows prediction error of less than 5% for predicting vehicle energy consumption.
Translation of a circulating melanoma microRNA profile into a solid tissue assay to improve diagnostic accuracy
Authors: Laar Ryan Van , King Samuel , McCoy Richard , Saad Mirette , Fereday Sian , Winship Ingrid , Uzzell Catherine , Landgren Anthony 
Published: May 2021

Abstract
Background: Successful treatment of cutaneous melanoma depends on early and accurate diagnosis of clinically suspicious melanocytic skin lesions. Multiple international studies have described the challenge of providing accurate and reproducible histopathological assessments of melanocytic lesions, highlighting the need for new diagnostic tools including disease-specific biomarkers. Previously, a 38-microRNA signature (“Mel38”) was identified in melanoma patient plasma and validated as a novel biomarker. In this study, Mel38 expression in solid tissue biopsies representing the benign naevi to metastatic melanoma spectrum is examined. Methods: Nanostring digital gene expression assessment of the Mel38 signature was performed on 308 formalin fixed paraffin embedded biopsies of naevi, melanoma in-situ and invasive melanoma. Genomic data were interrogated using hierarchical clustering, univariate, and multivariate statistical approaches. Classification scores computed from the Mel38 signature were analysed for their association with demographic data and histopathology results, including MPATH-DX class, AJCC disease stage and tissue subtype. Results: The Mel38 score can stratify higher-risk melanomas (MPATH-Dx Class V or more advanced) from lower-risk skin lesions (Class I-IV) with an area-under-the curve of 0.96 (P<0.001). The genomic score ranges from 0 to 10 and is positively correlated with melanoma progression, with an intraclass correlation coefficient of 0.85 with stage 0 to IV disease. Using an optimised classification threshold of ≥2.3 accurately identifies higher-risk melanomas, associated with poorer outcomes and more intensive suggested clinical actions with 95% sensitivity and 83% specificity. Multivariate analysis showed the score to be a significant predictor of malignancy, independent of technical and clinical covariates. Application of the Mel38 signature to spitz naevi reveal an intra-subtype profile, with elements of the profile in common to both naevi and melanoma. Conclusion: Melanoma-specific circulating microRNAs maintain their association with malignancy when measured in the hypothesized tissue of origin. The Mel38 signature is an accurate and reproducible metric of melanoma status, based on changes in microRNA expression that occur as the disease develops and spreads. Inclusion of the Mel38 score into routine practice would provide physicians with previously unavailable, personalised genomic information about their patient’s skin lesions. Combining molecular biomarker data with conventional histopathology data may improve diagnostic accuracy, healthcare resource utilisation, and patient outcomes.
HEA BeadChip™ technology in immunohematology
Authors: Paccapelo C. , Truglio F. , Villa M.A. , Revelli N. , Marconi M. 
Published: May 2021

Abstract
Classic methods to determine human red blood cell (RBC) antigens are based on serologic testing. Thanks to increased knowledge of the molecular basis associated with many blood group antigens, it is currently possible to predict their presence or absence on the red cell membrane. Several molecular techniques have been developed to detect the most important allelic variations attributable to single nucleotide polymorphisms. The human erythrocyte antigen (HEA) BeadChip™ system manufactured by BioArray Solutions (Immucor, Warren, NJ) is one of the commercial DNA array platforms currently available to predict HEAs by DNA analysis. This technology provides a useful tool to increase the inventory of antigen-negative RBC units and prevent immunization of patients who require chronic transfusion by providing compatible RBC units based on matching by DNA testing.
Immunohematology

2015;31:81–90.
Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms
Authors: Curtis B.R. 
Published: May 2021

Abstract
Drug-induced immune thrombocytopenia (DIIT) is a relatively uncommon adverse reaction caused by drug-dependent antibodies (DDAbs) that react with platelet membrane glycoproteins only when the implicated drug is present. Although more than 100 drugs have been associated with causing DIIT, recent reviews of available data show that carbamazepine, eptifibatide, ibuprofen, quinidine, quinine, oxaliplatin, rifampin, sulfamethoxazole, trimethoprim, and vancomycin are probably the most frequently implicated. Patients with DIIT typically present with petechiae, bruising, and epistaxis caused by an acute, severe drop in platelet count (often to <20,000 platelets/µL). Diagnosis of DIIT is complicated by its similarity to other non–drug-induced immune thrombocytopenias, including autoimmune thrombocytopenia, posttransfusion purpura, and platelet transfusion refractoriness, and must be differentiated by temporal association of exposure to a candidate drug with an acute, severe drop in platelet count. Treatment consists of immediate withdrawal of the implicated drug. Criteria for strong evidence of DIIT include (1) exposure to candidate drug–preceded thrombocytopenia; (2) sustained normal platelet levels after discontinuing candidate drug; (3) candidate drug was only drug used before onset of thrombocytopenia or other drugs were continued or reintroduced after resolution of thrombocytopenia, and other causes for thrombocytopenia were excluded; and (4) reexposure to the candidate drug resulted in recurrent thrombocytopenia. Flow cytometry testing for DDAbs can be useful in confirmation of a clinical diagnosis, and monoclonal antibody enzyme-linked immunosorbent assay testing can be used to determine the platelet glycoprotein target(s), usually GPIIb/IIIa or GPIb/IX/V, but testing is not widely available. Several pathogenic mechanisms for DIIT have been proposed, including hapten, autoantibody, neoepitope, drug-specific, and quinine-type drug mechanisms. A recent proposal suggests weakly reactive platelet autoantibodies that develop greatly increased affinity for platelet glycoprotein epitopes through bridging interactions facilitated by the drug is a possible mechanism for the formation and reactivity of quinine-type drug antibodies.
Immunohematology

2014;30:55–65.
Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007
Authors: Garratty G. , Arndt P.A. 
Published: May 2021

Abstract
This review updates new findings in drug-induced immune-hemolytic anemia (DIIHA) since the 2007 review in Immunohematology by these authors. Twelve additional drugs have been added to the three tables listing drugs associated with drug-dependent antibodies, drugs associated with drug-independent antibodies, and drugs associated with nonimmunologic protein adsorption. Other updated findings include (1) piperacillin is currently the most commonly encountered cause of DIIHA, (2) new data on blood group specificity of drug-dependent antibodies, (3) drug-dependent antibodies detected in healthy donors, (4) DIIHA associated with transplantation, and (5) DIIHA associated with chemotherapeutic drugs.
Immunohematology

2014;30:66–79.
Posttransplant maternal anti-D: a case study and review
Authors: Senzel L. , Avila C. , Ahmed T. , Gill H. , Hue-Roye K. , Lomas-Francis C. , Reid M.E. 
Published: May 2021

Abstract
Plasma from a 35-year-old, D– woman was found to have anti-D, -C, and -G at 5 weeks’ gestation and again at 8 weeks’ gestation, when she presented with a nonviable intrauterine pregnancy. The anti-D titer increased with a pattern that suggested it was stimulated by the 8-week pregnancy. Six years before this admission, the patient’s blood type changed from group O, D+ to group O, D– after a bone marrow transplant for aplastic anemia. Three years after transplant, the antibody screen was negative. After the patient was admitted for the nonviable pregnancy, the products of con-ception were found to be D+ by DNA testing for RHD. There were no documented transfusions or pregnancies during the interval in which anti-D appeared. The timing of the alloimmunization was unusual. In a subsequent pregnancy, fetal D typing was performed by molecular methods.
Immunohematology

2012;28:55–9.